INDUSTRY × Endocrine System Diseases × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 6 FDA
NCT03093116 2026-04-03

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 5 FDA
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 4 FDA
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 8 FDA
NCT03562897 2022-07-06

Evaluation of Ocoxin-ViusidĀ® in Advanced or Metastatic Ovarian Epithelial Cancer

Catalysis SL

Phase 2 Completed
40 enrolled
NCT00749502 2013-07-25

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Tesaro, Inc.

Phase 1 Completed
113 enrolled